» Articles » PMID: 16731041

Perspective-- FcRn Transports Albumin: Relevance to Immunology and Medicine

Overview
Journal Trends Immunol
Date 2006 May 30
PMID 16731041
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Recent evidence validates a forgotten 40-year-old hypothesis: the MHC-related Fc receptor for IgG (FcRn) protects albumin from intracellular catabolic degradation, as it does for IgG, accounting for the uniquely long half-lives of both molecules and explaining their direct concentration-catabolism relationships. Albumin and IgG bind to FcRn at low pH but not at physiological pH. These two ligands bind independently of one another by distinctive mechanisms and to different surfaces of the receptor. Kinetic studies of FcRn-deficient mice indicate that, at steady-state, FcRn salvages from the degradative pathway a similar amount of albumin as is produced by mice and almost four-times more IgG than is produced. Thirty-fivefold more albumin than IgG molecules are protected from degradation by FcRn per unit time. It can be inferred that FcRn is expressed in nearly all cells. This receptor, originally described as transporting IgG from the mother to the fetus or neonate, now has a wider role central to the homeostatic regulation and conservation of both albumin and IgG throughout life.

Citing Articles

Targeted Treatment of Sarcomas by Single Protein Encapsulated Doxorubicin with Undetectable Cardiotoxicity and Superior Efficacy.

Yu C, Huang F, Wang L, Liu M, Chow W, Ling X Cancers (Basel). 2025; 17(5).

PMID: 40075728 PMC: 11899045. DOI: 10.3390/cancers17050881.


Harnessing the potential of the NALT and BALT as targets for immunomodulation using engineering strategies to enhance mucosal uptake.

Seefeld M, Templeton E, Lehtinen J, Sinclair N, Yadav D, Hartwell B Front Immunol. 2024; 15:1419527.

PMID: 39286244 PMC: 11403286. DOI: 10.3389/fimmu.2024.1419527.


A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery.

Benjakul S, Anthi A, Kolderup A, Vaysburd M, Lode H, Mallery D PNAS Nexus. 2023; 2(12):pgad403.

PMID: 38077689 PMC: 10703496. DOI: 10.1093/pnasnexus/pgad403.


Single protein encapsulated SN38 for tumor-targeting treatment.

Yu C, Huang F, Wang K, Liu M, Chow W, Ling X J Transl Med. 2023; 21(1):897.

PMID: 38072965 PMC: 10712105. DOI: 10.1186/s12967-023-04778-0.


Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses.

Kawai A, Tokunoh N, Kawahara E, Tamiya S, Okamura S, Ono C J Clin Invest. 2023; 133(23).

PMID: 38038133 PMC: 10688985. DOI: 10.1172/JCI166827.